Completed PHASE1 INTERVENTIONAL 1-arm NCT00600002

Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma

A Phase I Clinical Trial of GM-CSF Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma

Sponsor: Edward Nelson

Conditions Pancreatic Cancer Resectable Pancreatic Adenocarcinoma

Interventions GM-CSF

Updated 7 times since 2017 Last updated: Jun 7, 2018 Started: Jun 30, 2004 Primary completion: Apr 30, 2018 Completion: Apr 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00600002, this PHASE1 trial focuses on Pancreatic Cancer and Resectable Pancreatic Adenocarcinoma and remains completed. Sponsored by Edward Nelson, it has been updated 7 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jul 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jun 2018 — Jul 2018 [monthly]

Active Not Recruiting PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Edward Nelson

Data source: University of California, Irvine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Orange, United States